Japan’s Kirin, Kyowa Merge To Strengthen Biotechnology Focus
This article was originally published in The Pink Sheet Daily
Kirin will acquire a 50.1 percent stake in Kyowa Hakko in a deal valued at close to ¥300 billion ($2.64 billion).
You may also be interested in...
Agreement with Japanese firm to develop and commercialize Phase I c-Met inhibitor ARQ 197 in Asia provides much-needed cash infusion.
Schering gains access to preclinical antibody, as well as biomarker profiling technology in deal worth up to $477.5 million
Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.